Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
NCT04174079Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2019
- Primary completion
- May 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of docetaxel and nedaplatin in Thoracic Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease-free survival at 5 years. Started Dec 2019; status: recruiting.
02
Drugs
docetaxelnedaplatin
03
Conditions
Thoracic Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04174079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174079.